Polylite Taiwan Co., Ltd. AI Stock Analysis
Polylite Taiwan Co., Ltd. (1813) AI Stock Analysis
Polylite Taiwan Co., Ltd.
(TPEx:1813)
The score is primarily constrained by severe revenue contraction, persistent losses, and a bearish technical trend. The relatively solid balance sheet and positive cash flow provide meaningful support, but the elevated P/E and lack of dividend yield limit the investment case.
Polylite Taiwan Co., Ltd. (1813) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 478.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 19.77K
- Price to Earnings (P/E)
- 61.1
- Beta (1Y)
- 0.23
- Revenue Growth
- -6.91%
- EPS Growth
- ―
- Country
- TW
- Employees
- 149
- Sector
- General
- Sector Strength
- 55
- Industry
- Semiconductors
Polylite Taiwan Co., Ltd. Business Overview & Revenue Model
Company Description
Polylite Taiwan Co., Ltd. is an international enterprise engaged in the fabrication, refinement, worldwide trade, and retail of a diverse selection of optical lenses, precision optical devices, and medical instruments. A key part of its product line...
Polylite Taiwan Co., Ltd. Financial Statement Overview
Summary
Financial performance is below average: the income statement score is weak at 15 due to severe revenue decline and persistent losses. A solid balance sheet and positive operating and free cash flow provide support, with balance sheet and cash flow scores of 75 and 60.
Income Statement
15Very NegativeBalance Sheet
75PositiveCash Flow
60Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 287.69M | 304.32M | 309.91M | 360.45M | 362.05M | 451.13M |
| Gross Profit | -47.72M | -52.32M | -59.80M | -3.93M | -22.26M | 19.58M |
| EBITDA | -48.33M | -1.81M | -54.00M | -11.38M | 11.54M | 45.52M |
| Net Income | 7.50M | -47.94M | -29.30M | 11.20M | 6.71M | -13.13M |
Balance Sheet | ||||||
| Total Assets | 968.25M | 931.76M | 1.01B | 1.05B | 1.14B | 1.26B |
| Cash, Cash Equivalents and Short-Term Investments | 146.40M | 138.21M | 119.04M | 150.27M | 210.44M | 305.97M |
| Total Debt | 238.04M | 217.53M | 241.96M | 204.99M | 251.25M | 323.77M |
| Total Liabilities | 304.44M | 270.75M | 302.59M | 276.56M | 315.79M | 426.21M |
| Stockholders Equity | 693.34M | 684.54M | 723.73M | 774.95M | 811.94M | 813.72M |
Cash Flow | ||||||
| Free Cash Flow | 61.93M | 36.53M | 30.39M | 36.75M | 16.05M | 60.11M |
| Operating Cash Flow | 67.64M | 46.81M | 35.20M | 46.22M | 31.93M | 78.68M |
| Investing Cash Flow | -16.24M | -10.05M | -67.63M | -9.11M | -14.79M | -19.50M |
| Financing Cash Flow | -12.73M | -18.84M | 13.48M | -97.52M | -99.45M | 29.27M |
Polylite Taiwan Co., Ltd. Peers Comparison
Overall Rating
TW:181349Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | TWD 478.01M | 61.08 | ― | ― | -6.91% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1813 | Polylite Taiwan Co., Ltd. | 10.45 | -2.75 | -20.83% | |
| TW:4115 | Sunder Biomedical Tech. Co., Ltd. | 6.97 | -1.43 | -17.02% | |
| TW:4170 | Vectorite Biomedical, Inc. | 11.00 | -2.60 | -19.12% | |
| TW:6660 | HMD Biomedical, Inc. | 12.70 | -11.05 | -46.53% | |
| TW:6999 | Han Biomedical, Inc. | 24.45 | -6.02 | -19.75% | |
| TW:7726 | CARILEX MEDICAL INC. | 32.15 | -3.95 | -10.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
